看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。2 D* k" |; Z, ^7 W
+ t3 C+ D E$ y1 K6 @# m
% i$ k. U) y2 Z- E, LCurrently available feasibility data for possible combination strategies. $ g' \+ T* e: B9 C
————————————————————————————————
' n9 {0 l$ b- C; ?Combination Feasibility according to preliminary data 8 X w% A, @5 ~7 Y* m9 k x
——————————————————————————————————
K) c/ ^ ~( K7 [+ S6 fBevacizumab + sorafenib Yes, reduced dose
W" j) j, F# d8 cBevacizumab + sunitinib† No 2 ~- h+ d7 ~7 @6 v9 e) U6 |, O1 o# r
Bevacizumab + temsirolimus Yes
9 _) ~ W+ o8 S7 O( N/ t4 h2 VBevacizumab + everolimus Yes
- W' `+ V/ p; LSorafenib + sunitinib ?
7 v `1 b, z" ?6 E# e6 f3 iSorafenib + temsirolimus Yes, reduced dose
9 s. \9 b4 G; S* K* sSorafenib + everolimus Yes, reduced dose , p2 M6 `* l$ w `# v" P. K
Sunitinib + temsirolimus† No
/ c: o% i: V/ zSunitinib + everolimus ?
# J& D X+ |" D3 ATemsirolimus + everolimus ? 4 i6 X. T& k) {( O, E( S* A
————————————————————
/ L; ~8 N9 f% {2 G†Led to US FDA warning.
) |8 q5 `* r) @" J0 q?: As yet unattempted combination.$ M8 @! L3 M5 F: M
|